Supernus Pharmaceuticals (NASDAQ:SUPN) Shares Pass Above Two Hundred Day Moving Average – Here’s Why

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) shares crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $49.31 and traded as high as $50.78. Supernus Pharmaceuticals shares last traded at $50.06, with a volume of 438,153 shares.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. Craig Hallum set a $65.00 target price on Supernus Pharmaceuticals in a report on Wednesday, February 25th. Wall Street Zen cut shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Sunday, March 8th. Stifel Nicolaus raised their price objective on shares of Supernus Pharmaceuticals from $50.00 to $55.00 and gave the company a “hold” rating in a research note on Friday, December 19th. Zacks Research cut shares of Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Thursday, January 29th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Monday, December 29th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $62.17.

Supernus Pharmaceuticals Trading Down 2.5%

The company has a market cap of $2.85 billion, a PE ratio of -72.82, a P/E/G ratio of 1.58 and a beta of 0.70. The company has a fifty day simple moving average of $50.99 and a two-hundred day simple moving average of $49.35.

Insider Transactions at Supernus Pharmaceuticals

In related news, Director Georges Gemayel sold 8,787 shares of the business’s stock in a transaction on Friday, March 6th. The shares were sold at an average price of $53.00, for a total transaction of $465,711.00. Following the completion of the transaction, the director owned 27,277 shares in the company, valued at approximately $1,445,681. The trade was a 24.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Frederick M. Hudson sold 5,369 shares of the stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $50.61, for a total value of $271,725.09. Following the completion of the transaction, the director directly owned 60,413 shares in the company, valued at $3,057,501.93. This trade represents a 8.16% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 120,881 shares of company stock valued at $6,139,356 over the last quarter. Insiders own 8.80% of the company’s stock.

Institutional Trading of Supernus Pharmaceuticals

A number of large investors have recently made changes to their positions in SUPN. State Street Corp grew its stake in Supernus Pharmaceuticals by 1.4% during the 4th quarter. State Street Corp now owns 2,219,228 shares of the specialty pharmaceutical company’s stock worth $110,296,000 after buying an additional 31,668 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Supernus Pharmaceuticals by 4.5% during the fourth quarter. Geode Capital Management LLC now owns 1,472,899 shares of the specialty pharmaceutical company’s stock worth $73,215,000 after acquiring an additional 62,875 shares during the last quarter. Loomis Sayles & Co. L P increased its holdings in shares of Supernus Pharmaceuticals by 12.7% in the 4th quarter. Loomis Sayles & Co. L P now owns 1,448,842 shares of the specialty pharmaceutical company’s stock valued at $72,007,000 after acquiring an additional 162,905 shares during the period. Stephens Investment Management Group LLC boosted its stake in Supernus Pharmaceuticals by 4.5% during the 4th quarter. Stephens Investment Management Group LLC now owns 1,406,522 shares of the specialty pharmaceutical company’s stock worth $69,904,000 after purchasing an additional 61,120 shares during the period. Finally, Woodline Partners LP boosted its stake in Supernus Pharmaceuticals by 63.5% during the 3rd quarter. Woodline Partners LP now owns 1,263,811 shares of the specialty pharmaceutical company’s stock worth $60,398,000 after purchasing an additional 490,835 shares during the period.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.